drugset / Trial / NCT02535286
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
Timeline
- Start
- 2015-09-18
- Primary completion
- 2021-11-04
- Completion
- 2021-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cosibelimab | Monoclonal antibody | — | Intravenous |
| Subject | Ublituximab | Monoclonal antibody | — | Intravenous |
| Subject | Umbralisib | Small molecule | — | Oral |